« Back
Home /
Bulevirtide

Bulevirtide

Item no.	HY-P3465-5mg
Manufacturer	MedChem Express
CASRN	2012558-47-1
Amount	5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitor
Specific against	other
Purity	99.16
Formula	C248H355N65O72
Citations	[1]Donkers JM, et al., Mechanistic insights into the inhibition of NTCP by myrcludex B. JHEP Rep. 2019 Aug 1;1(4):278-285.<br>[2]Volz T, et al., The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus. J Hepatol. 2013 May;58(5):861-7.<br>[3]Zhao K, et al., Upregulation of HBV transcription by sodium taurocholate cotransporting polypeptide at the postentry step is inhibited by the entry inhibitor Myrcludex B. Emerg Microbes Infect. 2018 Nov 21;7(1):186.<br>[4]Masetti C, et al. Bulevirtide for treatment of patients with HDV infection and compensated cirrhosis: A (huge?) step in the right direction. Liver Int. 2021 Jul;41(7):1441-1442.<br>[5]Cheng D, et al. Clinical effects of NTCP-inhibitor myrcludex B. J Viral Hepat. 2021 Jun;28(6):852-858.
Smiles	O=C(CNC(CCCCCCCCCCCCC)=O)N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N1[C@H](C(N[C@H](C(N2[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N3[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N4[C@H](C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N5[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N6[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N7[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(N)=O)=O)C(C)C)=O)CCCCN)=O)CC(N)=O)=O)C)=O)CCC(O)=O)=O)CCC7)=O)CC8=CNC9=CC=CC=C89)=O)CC%10=CNC=N%10)=O)CC(O)=O)=O)CCCCN)=O)CC(N)=O)=O)CCC6)=O)CC(N)=O)=O)CC%11=CC=CC=C%11)=O)CC(O)=O)=O)CC%12=CNC%13=CC=CC=C%12%13)=O)CC(O)=O)=O)CCC5)=O)CC(N)=O)=O)CC(N)=O)=O)CO)=O)CC(N)=O)=O)C)=O)=O)CC%14=CC=CC=C%14)=O)C)=O)CCC4)=O)CC(O)=O)=O)CC(C)C)=O)CCC(N)=O)=O)CC%15=CNC=N%15)=O)CC(O)=O)=O)CCC3)=O)CC%16=CC=CC=C%16)=O)CC%17=CC=CC=C%17)=O)=O)CC(C)C)=O)CCC2)=O)CC(N)=O)=O)CCC1)=O)C(C)C)=O)CO)=O)CC(C)C)=O)CC(N)=O)=O)[C@@H](C)O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Myrcludex B
Available
Product Description	Bulevirtide (Myrcludex B) is a NTCP inhibitor, a linear lipopeptide of 47 amino acids. Bulevirtide inhibits HBV and HDV entry into liver cells, blocks HBV infection in hepatocytes, and participates in HBV transcriptional suppression. Bulevirtide can be used in HDV infection and compensated cirrhosis research[1][2].
StorageTemperature	-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Shipping	Blue Ice
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	5398.86
Clinical_Information	Launched
Manufacturers Research_Area	Infection
Solubility	DMSO : 50 mg/mL (ultrasonic)
Manufacturers Target	HBV
Pathway	Anti-infection
Manufacturers Product type	Peptides

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

Request safety datasheet

Simple Order Order Subscription

Amount: 5 mg

available

Request delivery time